Tirzepatide
GYMINDA
Eli Lilly · Phase 2 · Active, not recruiting · Enrollment 285
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| Placebo + Tirzepatide | n/r | n/r | n/r | n/r |
| RO7204239 low dose + Tirzepatide | n/r | n/r | n/r | n/r |
| RO7204239 medium dose + Tirzepatide | n/r | n/r | n/r | n/r |
| RO7204239 high dose + Tirzepatide | n/r | n/r | n/r | n/r |
Not shown
- Placebo + Tirzepatide: endpoint not reported
- RO7204239 low dose + Tirzepatide: endpoint not reported
- RO7204239 medium dose + Tirzepatide: endpoint not reported
- RO7204239 high dose + Tirzepatide: endpoint not reported